Phylogenomic screening reveals idsA2 loss conferring nitroimidazole cross-resistance in Mycobacterium tuberculosis
Bicyclic nitroimidazoles, notably pretomanid and delamanid, represent cornerstone agents of WHO-recommended short-course BPaLM regimens for multidrug-resistant Mycobacterium tuberculosis (MDR-TB), yet clinical cross-resistance frequently emerges without canonical activating mutations. Here, to uncover non-canonical res...